Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 25, Issue 1 (January 2023) 25, 1–4; 10.4103/aja202230

ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment

Jeanny B Aragon-Ching

GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA

Correspondence: Dr. JB Aragon-Ching (Jeanny. Aragon-Ching@inova.org)

24-May-2022

Abstract

ARASENS is an international phase III trial demonstrating the beneficial role of darolutamide, a novel antiandrogen, when added to docetaxel and androgen deprivation therapy (ADT), with improvement in overall survival in men with metastatic castration-sensitive or hormone-sensitive prostate cancer. Darolutamide is a nonsteroidal androgen receptor antagonist that has been previously shown to improve metastasis-free survival in nonmetastatic castration-resistant prostate cancer. ARASENS showed that the risk of death was 32.5% lower in those who received additional darolutamide compared to ADT and docetaxel alone. Darolutamide also improved other secondary endpoints including time to castrate-resistant disease, time to pain progression, time to first skeletal-related event, and subsequent initiation of therapy. ARASENS, therefore, shows that darolutamide, in addition to ADT and docetaxel, as a form of upfront systemic intensification of “triplet” therapy for patients deemed chemotherapy-fit, represents a new standard of care for men with metastatic hormone-sensitive or castrate-sensitive prostate cancer and is anticipated to further change the landscape of treatment for this population of patients.

Full Text | PDF |

 
Browse:  249
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.